Status: Recruiting
AGNOSTIC THERAPY IN A PHASE II SINGLE-ARM STUDY IN FIRST-LINE TREATMENT OF DURVALUMAB IN ASSOCIATION WITH CARBOPLATIN OR CISPLATIN AND ETOPOSIDE IN PATIENTS AFFECTED BY EXTENSIVE STAGE - EXTRAPULMONARY SMALL CELL CARCINOMA
This is a phase II, single-arm, multicenter study to evaluate the activity and safety of durvalumab in combination with carboplatin or cisplatin plus etoposide in patients with treated ES-EPSCC.
Participants needed: 66
Trial details
Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Gruppo Oncologico Italiano di Ricerca ClinicaUpdated: Jun 18, 2024Locations: 1
Eligibility criteria
1. Age ≥ 18 years on day of signing informed consent. 2. Written informed consen... [+6]
Subjects with active, known or suspected autoimmune disease requiring systemic t... [+23]